E-LIB Suche - Ergebnisse für: Casneuf, T.

1

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CE..:

van de Donk, N. ; Cortes-Selva, D. ; Casneuf, T....
HemaSphere. 7 (2023) S2 - p. 28-29 , 2023

Link: https://doi.org/10.1097/..

2

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CE..:

N. van de Donk ; D. Cortes-Selva ; T. Casneuf...
http://journals.lww.com/10.1097/01.HS9.0000936256.84340.a7. , 2023

Link: https://doi.org/10.1097/..

3

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CE..:

van de Donk, N ; Cortes-Selva, D ; Casneuf, T...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171470/. , 2023

Link: http://www.ncbi.nlm.nih...

4

S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO-ENVIRONMENT..:

Köse, M. C. ; Bergiers, I. ; Malfait, M....
HemaSphere. 6 (2022) - p. 71-72 , 2022

Link: https://doi.org/10.1097/..

5

S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO-ENVIRONMENT..:

M. C. Köse ; I. Bergiers ; M. Malfait...
http://journals.lww.com/10.1097/01.HS9.0000843572.19189.b6. , 2022

Link: https://doi.org/10.1097/..

6

Daratumumab, bortezomib, and dexamethasone in relapsed or r..:

Weisel K ; Spencer A ; Lentzsch S...
info:eu-repo/semantics/altIdentifier/wos/WOS:000566236600001. , 2020

Link: https://hdl.handle.net/1..

7

Genomic Profiling of Smoldering Multiple Myeloma Identifies..:

Bustoros, M ; Sklavenitis-Pistofidis, R ; Park, J...
https://discovery.ucl.ac.uk/id/eprint/10101951/3/Yong_SMM%20manuscript_JCO_revised_FINAL.pdf. , 2020

Link: https://discovery.ucl.ac..

8

Daratumumab, bortezomib, and dexamethasone in relapsed or r..:

Weisel, K. (Katja) ; Spencer, A. (Andrew) ; Lentzsch, S. (Suzanne)...
http://repub.eur.nl/pub/129801. , 2020

Link: http://repub.eur.nl/pub/..

9

Current practice in approaching controversial diagnostic an..:

Cuyle, P-J ; Geboes, K ; Carton, S...
boreal:263202. , 2020

Link: http://hdl.handle.net/20..

10

Current practice in approaching controversial diagnostic an..:

Cuyle, P-J ; Geboes, K ; Carton, S...
boreal:263202. , 2020

Link: http://hdl.handle.net/20..

11

Daratumumab, lenalidomide, and dexamethasone in relapsed/re..:

Kaufman, J.L. (Jonathan L.) ; Dimopoulos, M.A. (Meletios A.) ; White, D.J. (Darrell J.)...
https://hdl.handle.net/10171/65790. , 2020

Link: https://hdl.handle.net/1..

12

Daratumumab, bortezomib, and dexamethasone in relapsed or r..:

Weisel, K ; Spencer, A ; Lentzsch, S...
issn:1756-8722. , 2020

Link: http://hdl.handle.net/11..

13

Daratumumab, bortezomib, and dexamethasone in relapsed or r..:

Weisel K ; Spencer A ; Lentzsch S...
info:eu-repo/semantics/altIdentifier/pmid/32819447. , 2020

Link: http://hdl.handle.net/24..

14

Daratumumab, lenalidomide, and dexamethasone in relapsed/re..:

Kaufman, J. L ; Dimopoulos, Meletios ; White, D...
Blood Cancer Journal. , 2020

Link: https://ddd.uab.cat/reco..

15

Daratumumab, lenalidomide, and dexamethasone in relapsed/re..:

Kaufman, JL ; Dimopoulos, MA ; White, D...
https://eprints.whiterose.ac.uk/168243/1/Kaufman.POLLUX%20Cyto%20Risk.BCJ.2020.pdf. , 2020

Link: https://eprints.whiteros..